四川医学2011，Vol.32Issue(1)：53-55,3.
吉西他滨与奥沙利铂联合治疗对晚期非小细胞肺癌无进展生存期的影响
Effect on the progress-free survival of patients with advanced non-small cell lung cancer treated with gemcitabine and oxaliplatin
申泓 1白顺滟 1肖思洁1
作者信息
- 1. 成都363医院肿瘤科,四川,成都,610041
- 折叠
摘要
Abstract
Objective Observe the efficacy and progress-free survival of the combination of Oxaliplatin combined with Gemcitabine in the treatment of advanced non-small cell lung cancer( NSCLC). Methods There were 38 cases of advanced NSCLC patients who were treated with Oxaliplatin and Cemcitabine including 25 cases of male and 13 cases of female. Gemcitahine at the dose of 10000mg/m2 was administered on day 1 and 8 by intravenous infusion , followed by Oxaliplatin at 130mg/m2 given on day 1. The chemotherapy cycles were repeated every 21 days , and the patients received at least 2 cycles. Results 3 of them achieved complete remission( CR) , 12 got partial remission( PR) , 16 patients attain stable disease ( SD ) , while 3 of them entered into progressive disease( PD) . The overall response rate was 47. 22％ . The main toxicities was myelosuppression. Conclusion The treatment of Oxaliplatin combined with Gemcitabine is effective , meanwhile has low toxicity and less side reactions . andit could improve the local control rate and one-year survival rate.关键词
非小细胞肺癌/吉西他滨/奥沙利铂/化学治疗分类
医药卫生引用本文复制引用
申泓,白顺滟,肖思洁..吉西他滨与奥沙利铂联合治疗对晚期非小细胞肺癌无进展生存期的影响[J].四川医学,2011,32(1):53-55,3.
